Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CRHBP | P24387 | 2/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408107 | 0.94 | LMNA (0.59) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL14499098 | 0.89 | RAB9A (0.45) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL30061260 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL15503174 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL30301362 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL14156065 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL29664909 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL12533554 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL22118102 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL15503300 | 0.89 | MAPT (0.53) | LMNASMN1; SMN2CRHBPCRHR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | LMNA 2297/4885SMN1; SMN2 146/4885CRHBP 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.